Abstract:Background Carfilzomib (CFZ) treatment increases the survival of patients with relapsed/refractory MM, but it is associated with a higher incidence of cardiovascular adverse events not commonly observed after bortezomib (BTZ). Both CFZ and BTZ inhibit the rate-limiting proteasome beta 5 subunit activity at lower concentrations. However, only CFZ co-inhibits the activity of proteasome beta 5 and beta 2 subunits at higher doses, in contrast to the beta 5 and beta 1 co-inhibition provided by high dose BTZ. We hypothesized that the unique beta 5 and beta 2 subunit inhibition pattern explains the CFZ-related acute cardiotoxicity. Methods Isolated primary murine cardiomyocytes treated with BTZ, CFZ or specific inhibitors for the beta 5, beta 2 and beta 1 proteasome subunits were used as in vitro model to assess cardiomyocyte contractility by time lapse video-microscopy in conjunction with motion vector image analysis. The effects of acute proteasome inhibition after CFZ or BTZ treatment was studied in vivo in the heart and bone marrow 1 hour post treatment with a multi-omics approach at the single cell-genomic, proteomic and metabolomic level. Selectivity of proteasome subunit inhibition was confirmed with the activity based chemical probes. All data was evaluated with R v.3.5.1 (2018-07-02) and Matlab 2020a. Results CFZ resulted in co-inhibition of beta 5 and beta 2 proteasome subunit activity in cardiomyocytes, in contrast to beta 5 and beta 1 inhibition by BTZ. CFZ, or the combination of beta 5 and beta 2 specific proteasome inhibitors induced acute impairment of cardiomyocyte contractility, in contrast to BTZ or the combination of beta 5 and beta 1 inhibitors. CFZ caused significant quantitative proteomic changes related to cardiomyocyte metabolism that differed from BTZ-related proteomic changes. Single-cell RNA sequencing of murine hearts revealed that CFZ impairs ATP synthesis in cardiomyocytes. Metabolomic analysis of murine hearts revealed increased levels of angiotensin after CFZ treatment, in contrast to BTZ treatment. Co-treatment of cardiomyocytes with CFZ and valsartan prevented CFZ-induced cardiomyocyte toxicity. Thus, our results suggest a key role of the renin-angiotensin system in the pathogenesis of CFZ-induced acute cardiac toxicity. Conclusion Our data suggest that CFZ specifically impairs cardiac contractility in a dose-dependent manner through its unique proteasome beta 5 and beta 2 subunit co-inhibition pattern, in contrast to BTZ. CFZ leads to more efficient functional proteasome inhibition in cardiomyocytes, impairs cardiomyocyte metabolism and activates the local renin-angiotensin-system, inducing acute cardiotoxicity. Inhibition of the renin-angiotensin system pathway with valsartan mitigated cardiomyocyte contractile impairment, providing a rational strategy to prevent CFZ-induced acute cardiac toxicity.

Abstract 15012: Lactate Dehydrogenase B and Pyruvate Oxidation Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: A Multi-omics Study

Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis

Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma

Abstract P1184: Spatiotemporal Proteomics Approach To Discern New Features Of Carfilzomib-mediated Cardiotoxicity

Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma

P-158: Carfilzomib-induced acute cardiotoxicity is mediated through angiotensin and caused by cardiomyocyte energy depletion

Metabolomics Point out the Effects of Carfilzomib on Aromatic Amino Acid Biosynthesis and Degradation

Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity

Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma

Carfilzomib induced cardiotoxicity in a multiple myeloma patient

Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes

Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy

Abstract 499: Modeling Carfilzomib Induced Cardiotoxicity Using Human Induced Pluripotent Stem Cell-derived Cardiomyocytes

Cardiovascular Toxicity of Carfilzomib: the Real-World Evidence Based on the Adverse Event Reporting System Database of the FDA, the United States

Carfilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)

Hypertension, smoking, and preexistence of multiple cardiac risk factors correlate with carfilzomib-induced cardiovascular adverse events in a racially diverse population

Canagliflozin differentially modulates carfilzomib-induced endoplasmic reticulum stress in multiple myeloma and endothelial cells

Identifying metabolic adaptations characteristic of cardiotoxicity using paired transcriptomics and metabolomics data integrated with a computational model of heart metabolism

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells Via Modulation of Ros Generation and Erk1/2

Elucidating Carfilzomib’s Induced Cardiotoxicity in an In Vivo Model of Aging: Prophylactic Potential of Metformin

Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity